Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance (opens in a new tab)

medicalxpress.com · 2026-10-07

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 5Not checkedResearchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 5Not checkedThe findings, published in Nature, reveal for the first time that a single transfer RNA, or tRNA, can control the identity of prostate cancer cells and influence their response to therapy.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 5Not checkedAcross prostate cancer cell lines, mouse models and tumor samples from patients, levels of tRNA1Arg(UCU) were high in androgen receptor–dependent cells but diminished in less androgen receptor–dependent, treatment-resistant tumors.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 5Not checkedThe article says treatment-resistant tumors, when given the specific tRNA, could go back to being sensitive to treatments targeting the androgen receptor.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 5Not checkedThe story says the finding could be applied as a biomarker or therapeutic target for aggressive prostate cancer, and possibly extended to other cancers such as lung and breast cancers that undergo identity switches after treatment.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

tRNA dosage regulates lineage dependency and resistance in prostate cancer

Nature · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 41 candidate papers

Candidate

Author response for "Identifying an Elusive C–N Coupling Product: Toward Reliable Detection in CO2/NO2– Electrolysis"

2026 · Crossref

Source (opens in a new tab)
Candidate

Author response for "Hydrogel-integrated multimodal physiological monitoring and modulation systems"

2026 · Crossref

Source (opens in a new tab)

And 35 more candidates considered.